- Home
- LFCR vs ABEO Comparison
LFCR vs ABEO Comparison
Compare LFCR & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFCR
- ABEO
- Stock Information
- Founded
- LFCR 1986
- ABEO 1974
- Country
- LFCR United States
- ABEO United States
- Employees
- LFCR N/A
- ABEO N/A
- Industry
- LFCR Biotechnology: Pharmaceutical Preparations
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- LFCR Health Care
- ABEO Health Care
- Exchange
- LFCR Nasdaq
- ABEO Nasdaq
- Market Cap
- LFCR 308.8M
- ABEO 332.0M
- IPO Year
- LFCR N/A
- ABEO 1980
- Fundamental
- Price
- LFCR $7.61
- ABEO $6.83
- Analyst Decision
- LFCR Buy
- ABEO Strong Buy
- Analyst Count
- LFCR 4
- ABEO 6
- Target Price
- LFCR $8.00
- ABEO $18.17
- AVG Volume (30 Days)
- LFCR 108.3K
- ABEO 702.3K
- Earning Date
- LFCR 08-07-2025
- ABEO 08-14-2025
- Dividend Yield
- LFCR N/A
- ABEO N/A
- EPS Growth
- LFCR N/A
- ABEO N/A
- EPS
- LFCR N/A
- ABEO 0.99
- Revenue
- LFCR $128,867,000.00
- ABEO $400,000.00
- Revenue This Year
- LFCR $4.78
- ABEO N/A
- Revenue Next Year
- LFCR $12.02
- ABEO $339.63
- P/E Ratio
- LFCR N/A
- ABEO $6.91
- Revenue Growth
- LFCR 0.47
- ABEO N/A
- 52 Week Low
- LFCR $3.68
- ABEO $3.93
- 52 Week High
- LFCR $8.85
- ABEO $7.54
- Technical
- Relative Strength Index (RSI)
- LFCR 53.94
- ABEO 52.71
- Support Level
- LFCR $7.33
- ABEO $6.70
- Resistance Level
- LFCR $7.73
- ABEO $7.15
- Average True Range (ATR)
- LFCR 0.30
- ABEO 0.31
- MACD
- LFCR 0.03
- ABEO -0.02
- Stochastic Oscillator
- LFCR 65.33
- ABEO 46.62
About LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.